-
Gut Microbial H2S, GLP-1, and Host Metabolism
2026-08-29
Qi et al. identify Desulfovibrio-derived hydrogen sulfide as a microbiota-to-host signal that suppresses intestinal GLP-1 production by disrupting mitochondrial respiration and activating the unfolded protein response in enteroendocrine L cells. The study links this mechanism to metabolic dysfunction in male mice and shows that pharmacological interruption of the Desulfovibrio–H2S axis can restore GLP-1-related metabolic protection.
-
Cisplatin Workflows for DNA Damage and Resistance
2026-08-28
Build more interpretable Cisplatin assays by connecting DNA crosslinking, apoptosis, repair signaling, and treatment resistance in one workflow. This guide translates a recent nasopharyngeal carcinoma study into practical dose-response, combination, mechanistic, and xenograft study designs.
-
PLGA Nano-Adjuvant Enhances Mucosal Immunity
2026-08-28
A 2026 Poultry Science study developed PEI-LSP-RA-PLGA, a multilayer PLGA nano-adjuvant designed to combine sustained release, intestinal targeting, and immune regulation in chicks receiving an inactivated H9N2 vaccine. The formulation increased systemic IgG and intestinal IgA responses while linking intestinal targeting to CCR9, CCR6, CCL20, and CCL25 signaling and downstream pathways associated with mucosal immunity.
-
AG-221 (Enasidenib) in IDH2-Mutant AML Research
2026-08-27
AG-221, also called Enasidenib, is a selective mutant IDH2 inhibitor for acute myeloid leukemia research. It suppresses abnormal 2-hydroxyglutarate production and supports differentiation-focused studies, while clinical evidence applies specifically to patients with relapsed or refractory AML carrying IDH2 mutations.
-
X-Gal: From Clone Screening to Translational Insight
2026-08-27
X-Gal is more than a blue-white colony screening reagent: it is a mechanistically defined reporter substrate that can help translational researchers connect construct integrity, gene regulation, and pathway hypotheses. This article links molecular cloning fundamentals with emerging iRhom2 biology while clarifying where X-Gal is validated, where it is exploratory, and how to build more decision-ready workflows.
-
ROS–PDH Metabolic Rewiring in Melanoma
2026-08-26
Cesi et al. demonstrate that BRAF or MEK pathway inhibition increases reactive oxygen species, activates pyruvate dehydrogenase kinases, and suppresses PDH-dependent oxidative metabolism in melanoma cells. Their results identify PDK inhibition as a mechanistically informed strategy for suppressing BRAF-mutant and BRAF-inhibitor-resistant melanoma growth.
-
ATG4B Nuclear Translocation Drives AML DNA Repair Failure
2026-08-26
This 2025 Advanced Science study identifies a mechanistic link between energy deficiency, nuclear ATG4B, impaired DNA repair, and acute myeloid leukemia progression. The work suggests that blocking ATG4B can restore PRMT1–MRE11 signaling, reduce genomic instability, and improve outcomes in cellular and mouse AML models.
-
RESTRICT-seq Maps Epigenetic Dependencies in SCC
2026-08-25
The bioRxiv preprint introduces RESTRICT-seq, a time-gated CRISPR screening framework designed to resolve when genetic perturbations become important during squamous cell carcinoma resistance. Its findings support a dynamic view of resistance biology in which epigenetic dependencies may be missed by conventional endpoint screens, with implications for mechanistic validation and therapeutic timing.
-
Sulfo-Cy3 NHS Ester in Vascular Translation
2026-08-25
A mechanistic and translational perspective on using Sulfo-Cy3 NHS Ester to interrogate the AIBP–LRP2–HDL–miR-223 axis and CXCR4-positive endothelial remodeling in ischemic vascular disease.
-
SAR405: A Precision Vps34 Inhibitor Workflow
2026-08-24
SAR405 enables selective Vps34 perturbation for dissecting autophagy, vesicle trafficking, lysosome biology, and emerging nuclear PI3P functions. This workflow combines practical dosing guidance with orthogonal controls that help distinguish pathway-specific effects from nonspecific toxicity or assay artifacts.
-
AIBP-LRP2 Axis Restricts CXCR4+ Collateral Growth
2026-08-24
Zhu et al. identify an AIBP-LRP2-HDL-miR-223 pathway that limits the expansion of CXCR4+ stemlike capillary endothelial cells after ischemia. The study links lipid handling to collateral circulation and proposes that restoring CXCR4 activity could support revascularization, although the evidence remains primarily mechanistic and preclinical.
-
PLGA Nano-Adjuvant Enhances Mucosal Immunity in Chicks
2026-08-23
The reference study develops PEI-LSP-RA-PLGA, a double-layer PLGA nanoparticle adjuvant designed to combine sustained delivery, intestinal targeting, and immune regulation in chicks vaccinated against H9N2 avian influenza. Its reported increases in serum IgG and intestinal IgA, together with pathway-level evidence involving CCR9, CCR6, Toll-like receptor, NOD-like receptor, and IgA-production networks, support a mechanistic framework for coordinating systemic and mucosal immunity.
-
Amikacin Sulfate: NTM Research Guide
2026-08-22
Amikacin Sulfate is an aminoglycoside research compound with dose-dependent bactericidal activity against selected Mycobacterium avium complex and Staphylococcus aureus models. Its reported intracellular uptake and granuloma-directed distribution support research into targeted drug delivery of amikacin, while toxicity and assay-specific exposure limits remain important constraints.
-
X-Gal: Mechanism and Blue-White Screening
2026-08-21
X-Gal, also called 5-bromo-4-chloro-indolyl-β-D-galactopyranoside, is a chromogenic β-galactosidase substrate for visual clone selection. Its lacZα-dependent blue-white readout supports rapid molecular cloning decisions, while product specifications define its identity, solubility, purity, and storage requirements.
-
ATG4B Nuclear Translocation and AML DNA Repair
2026-08-20
The reference study identifies an unexpected mechanism connecting energy deficiency with genomic instability in acute myeloid leukemia: nuclear ATG4B binds PRMT1 and suppresses PRMT1-dependent MRE11 methylation. Across patient-derived, genetically induced, and xenograft models, ATG4B inhibition improved DNA damage responses, reduced malignant progression, and extended survival, providing a mechanistic framework for studying metabolic control of DNA repair.